Thrombotic microangiopathy
MONDO:0019737The syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation.
154 clinical trials for this condition and its sub-types, 26 tagged with Thrombotic microangiopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Thrombotic microangiopathy
-
Thrombocytopenic purpura 8 trials · 116 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
-
Atypical hemolytic-uremic syndrome 19 trials
4 sub-types
Most studied deeper sub-types
-
Abandoned study: could a drug fix Chemo-Related kidney injury?
Disease control CancelledThis study planned to test the drug eculizumab in cancer patients who developed kidney damage from the chemotherapy drug gemcitabine. The goal was to see if eculizumab could help the kidneys recover. However, the trial was withdrawn before any patients were enrolled, so no data w…
Phase 3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental drug offered to stem cell transplant patients with rare blood disorder
Disease control ApprovedThis program provides narsoplimab, an experimental drug, to patients who develop a serious blood clotting condition called thrombotic microangiopathy after a stem cell transplant. The goal is to offer treatment when no other options are available. Patients must have had a stem ce…
Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Cheap antioxidant could replace costly drugs for Post-Transplant blood disorder
Disease control OngoingThis study tests whether N-acetylcysteine (NAC), a common antioxidant, can treat a severe blood vessel condition called TA-TMA that can happen after a stem cell transplant. Current treatments are either ineffective or very expensive. The trial will enroll 44 adults diagnosed with…
Phase 2/3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Promising ITP drug trial pulled before it even started
Disease control CancelledThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Phase 1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC
-
Could an immune treatment ease long COVID brain fog?
Symptom relief By invitation onlyThis study tests whether a treatment called IVIG (intravenous immunoglobulin) can help with ongoing neurological symptoms after COVID-19, like dizziness, trouble walking, or memory problems. About 45 adults who had COVID-19 at least 12 weeks ago will receive either IVIG or a plac…
Phase 2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC